EXACT Sciences Current Valuation
| EXASDelisted Delisted Stock | USD 1,812 0.00 0.00% |
EXACT Sciences is priced without meaningful earnings support — a reading that maps directly to negative margins and limited earnings visibility. On asset measures, EXACT Sciences carries a 8.34x P/B and 6.17x P/S. Market capitalization stands at 20 B against an enterprise value of 21.6 B.
Above Model Estimate
Today
The intrinsic value estimate for EXACT Sciences is based on a 3 months horizon. Negative profit margins (-6.4%) signal ongoing profitability risk influencing market valuation. Extending the time horizon generally improves valuation stability.
EXACT Sciences' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account all liquid assets, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Enterprise Value | = | Market Cap + Debt | - | Cash |
Current EXACT Sciences Current Valuation | 21.58 B |
Most of EXACT Sciences' key ratios, such as Current Valuation, are part of a framework for finding mispriced stocks. The link between EXACT Sciences' core metrics and market price helps shape the investment case. Cross-checking multiple valuation measures reduces the risk of drawing conclusions from one metric's blind spots. We also note other views for learning purposes where useful. A price-to-book ratio of 8.34 helps frame the market's assessment of EXACT Sciences' asset base.
CompetitionFundamental Drivers Relationships
Current Valuation Peer Comparison
Peer comparison on Current Valuation is one of the most widely used methods for evaluating EXACT Sciences relative to competitors. Comparing EXACT Sciences' Current Valuation against peers surfaces securities trading below their model-implied intrinsic value estimate in the group.EXACT Sciences is currently under evaluation in current valuation relative to competitors.
Important Fundamentals
| Return On Equity TTM | -0.0866 | |||
| Return On Asset TTM | -0.0159 | |||
| Profit Margin TTM | -0.064 | |||
| Operating Margin TTM | -0.0928 | |||
| Current Valuation | 21.58 B | |||
| Shares Outstanding | 190.89 M | |||
| Shares Owned By Insiders | 1.20 % | |||
| Shares Owned By Institutions | 86.47 % | |||
| Number Of Shares Shorted | 7.4 M | |||
| Price To Earnings TTM | -38.17 X | |||
| Price To Book TTM | 8.34 X | |||
| Price To Sales TTM | 6.17 X | |||
| Revenue TTM | 3.25 B | |||
| Gross Profit TTM | 2.26 B | |||
| EBITDA TTM | 122.5 M | |||
| Net Income TTM | -207.95 M | |||
| Cash And Equivalents TTM | 728.04 M | |||
| Cash Per Share TTM | 4.11 X | |||
| Total Debt TTM | 2.52 B | |||
| Debt To Equity TTM | 0.77 % | |||
| Current Ratio TTM | 2.48 X | |||
| Book Value Per Share TTM | 12.58 X | |||
| Cash Flow From Operations TTM | 491.44 M | |||
| Short Ratio TTM | 3.23 X | |||
| Earnings Per Share | -1.10 X | |||
| Price To Earnings To Growth | -1.07 X | |||
| Target Price | 106.3 | |||
| Number Of Employees | 7.1 K | |||
| Trailing Beta | 1.44 | |||
| Market Capitalization TTM | 20.03 B | |||
| Total Asset TTM | 5.86 B | |||
| Retained Earnings TTM | -4.71 B | |||
| Working Capital TTM | 914.7 M | |||
| Current Asset TTM | 325.86 M | |||
| Current Liabilities TTM | 26.72 M | |||
| Net Asset | 5.86 B |
Financial Metrics, Fundamentals & Methodology
EXACT Sciences's core fundamentals cover profitability, capital efficiency, and funding structure. The company is currently operating at a loss. Overall market capitalization tier is large-cap. In recent filings, EXACT Sciences reported revenue of 3.25 billion, EPS loss of 1.1, negative operating margin of 9.28% as of the latest reporting period.
EXACT Sciences metrics draw on periodic company reporting and market reference feeds, standardized for cross-period comparison. Reported income, balance-sheet, and cash-flow fields adhere to GAAP or IFRS presentation rules.
Editorial review and methodology oversight provided by: Ellen Johnson, Member of Macroaxis Editorial Board